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Placebo and nocebo effects have been shown to influence subjective symptoms such 
as itch. These effects can be induced by influencing outcome expectations through, 
for example, combining the application of an inert substance (e.g., a cream) with verbal 
suggestions on the anticipated effects of this substance. Interestingly, placebo effects 
also occur when it is known that a treatment is inert (i.e., open-label placebo). However, 
no study to date has examined the efficacy of negative and positive verbal suggestions 
under similar open-label and closed-label (i.e., concealed placebo/nocebo) conditions 
in itch. A randomized controlled between-subjects study design was applied in which 
healthy volunteers (n = 92) were randomized to 1) an open-label positive verbal suggestion 
group, 2) a closed-label positive verbal suggestion group, 3) an open-label negative 
verbal suggestion group, or 4) a closed-label negative verbal suggestion group. Verbal 
suggestions were made regarding the topical application of an inert substance. Itch 
was evoked experimentally by histamine iontophoresis at baseline and again following 
suggestions. Itch expectations, self-reported itch during and following iontophoresis, and 
skin response parameters were measured. Positive suggestions were found to result 
in significantly lower expected itch than were negative suggestions in both open- and 
closed-label conditions. No effects of the suggestions on itch during iontophoresis were 
found, but significantly lower itch was reported in the 4 min following iontophoresis in the 
(combined open- and closed-label) positive compared with negative verbal suggestion 
groups. In addition, a smaller increase in skin temperature was found in the positive 
compared with negative suggestion groups. The findings illustrate a potential role of 
(open- and closed-label) placebo for optimizing expectations and treatment effects for 
itch in clinical practice.
Clinical Trial Registration: Netherlands Trial Register, trial number: NTR6530.
Keywords: placebo, nocebo, itch, suggestion, pruritus
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INTRODUCTION
Itch is the most common somatosensory symptom in 
dermatological conditions. It is a hallmark symptom of atopic 
eczema (1), and its prevalence in psoriasis is high (2). Moreover, 
itch is a common symptom of various other disorders, including 
kidney failure, liver disease, cancer, allergy, and diabetes mellitus 
(3–5). Due to its high prevalence—approximately 8% of the 
general population and over 50% of dermatological patients—
the burden of itch and its impact on society are high (6, 7). Often, 
patients report significantly lowered quality of life, increased 
depressive and anxious symptoms, and sleep disturbances due 
to chronic itch (8). While current treatments aim to suppress 
itch through pharmacological interventions, oftentimes, limited 
effects and significant side effects are reported (3, 9). As such, it is 
important to identify factors that contribute to treatment efficacy.
One of the factors that may be especially relevant for 
treatment outcomes is the placebo effect. Placebo effects are 
defined as beneficial effects of otherwise pharmacologically inert 
substances (10, 11) and have been studied in a variety of medical 
conditions and symptoms, including itch and pain (12–14). 
Multiple pathways through which these effects can be elicited 
have been identified, including associative learning processes, 
social learning, or instructional learning (12, 15–17). Within 
these pathways, expectancy is a key component. To illustrate, a 
positive expectation may be elicited through past experiences 
with the beneficial effects of a certain type of medication 
(associative learning), through observation of treatment 
efficacy in others (social learning), or through receiving 
positive (verbal) information about a treatment (instructional 
learning) (17). In turn, this positive expectation can then result 
in psychoneurobiological changes and symptom reduction (18, 
19). On the other hand, when expectations regarding a treatment 
outcome are low or negative outcomes are expected, symptoms 
may worsen or the occurrence of treatment side effects may 
increase, known as the nocebo effect (12, 20).
The current literature indicates that at least 30% of itch reduction 
in clinical practice might be attributable to placebo effects (21). 
Placebo and nocebo effects can be experimentally induced for itch 
by changing expectations through verbal suggestions regarding 
inert treatments or through the use of associative learning 
mechanisms (22–28). However, not all studies confirm these 
findings (28, 29). In addition, there is some evidence that it may 
be necessary to combine multiple placebo induction methods 
(e.g., associative learning and positive suggestions) and that a 
single induction method may not be sufficient to elicit significant 
placebo effects (22). Hence, further study of the circumstances 
under which placebo effects may be elicited for itch is relevant.
Most studies on placebo effects take on a traditional 
approach, in which patients or healthy individuals are told that 
a pharmacologically effective substance (e.g., a pill or cream) is 
given, whereas in reality, the substance is pharmacologically inert 
(30, 31). While this concealing or deceptive approach is useful for 
studying the underlying mechanisms of placebo effects in general, 
it may become problematic when it comes to utilizing these effects 
in clinical practice, where concealment or deception regarding the 
treatment provided brings along ethical issues. For a long time, it 
was believed that this would prevent strategic use of the placebo 
effect in clinical practice (30). In the past years, however, studies 
have demonstrated that placebo effects can also occur when it is 
explicitly told that, although a given substance is inert, placebo 
effects may still help in alleviating symptoms. These so-called 
open-label placebo effects have been found to significantly 
reduce symptoms of irritable bowel syndrome, depression, 
attention deficit hyperactivity disorder, chronic low back pain, 
and allergic rhinitis (31–39). Most of these studies induce open-
label placebo effects through a combination of an attribute (e.g., 
an inert pill) that may trigger previously learned associations 
between medicine and symptom reduction in general, and a 
scripted briefing in which the positive effects of placebo pills are 
emphasized (a suggestive framework) (31–34, 36–38). Findings 
on whether these effects can be attributed to the provided pill or 
the provided explanation alone are contradictory (35, 39, 40).
In view of the previous findings, further research is needed to 
demonstrate the efficacy of both open-label and closed-label (i.e., 
concealed) placebo effects for itch. It is not yet known whether 
effect sizes of open-label and closed-label placebo effects are 
comparable. Moreover, no study to date has investigated whether 
nocebo effects can be induced under both closed-label and 
open-label conditions for itch. To this end, we investigated in the 
current study whether negative or positive outcome expectations, 
induced by a suggestive framework (negative and positive verbal 
suggestions, provided in an open-label and closed-label context) 
combined with an attribute (an inert tonic), can influence self-
reported itch during an experimental itch induction by histamine 
in healthy volunteers. We primarily tested the effects of the positive 
and negative suggestions on itch by combining open- and closed-
label groups. Secondarily, we tested these effects for open-label and 
closed-label contexts separately to see whether these effects were 
comparable, and we investigated the effects of suggestions on other 
markers of the response to this test, for example, the physical skin 
response to histamine. We expected a decrease in itch following 
positive verbal suggestions compared with an increase in itch 
following negative verbal suggestions for both the open-label and 
closed-label conditions.
MATERIALS AND METHODS
The study was approved by the Medical Ethical Committee 
at the Leiden University Medical Center, the Netherlands 
(NL58792.058.16), and registered in the Dutch Trial Register 
(NTR6530). The study was performed in accordance with the 
Declaration of Helsinki (41). All participants provided written 
informed consent.
Participants
Healthy male and female participants were recruited through 
advertisements at Leiden University and through social media 
(e.g., Facebook). Inclusion criteria consisted of an age between 
18 and 35 years and a good understanding of the Dutch written 
and spoken language. Interested volunteers were excluded in 
case of self-reported severe somatic or psychological morbidity 
that could interfere with the participant’s safety or study protocol 
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[e.g., heart or lung diseases, histamine intolerance, or Diagnostic 
and Statistical Manual of Mental Disorders - Fourth Edition 
Text Revised (DSM-IV-TR) psychiatric diagnoses]; current 
chronic itch or pain complaints; current use of analgesics, anti-
inflammatory medication, antihistamines, or antibiotics; and 
(suspected) pregnancy. Participants were asked to refrain from the 
consumption of heavy meals, caffeine, and smoking 2 h, exercise 
12 h, and alcohol as well as drugs 24 h prior to the sessions to 
prevent potential influences on study outcomes. Adherence to 
these lifestyle guidelines, as well as the exclusion criteria, was 
verified at the start of each session by means of interviewing.
Study Design
A between-subjects, single-blinded, randomized controlled 
experimental trial design was applied. Eligible participants 
were randomized to (I) an open-label positive verbal suggestion 
(VS) group, (II) a closed-label positive VS group, (III) an open-
label negative VS group, or (IV) a closed-label negative VS 
group. Randomization sequence was acquired using an online 
random number generator (www.random.org, Dublin, Ireland). 
Allocation was not concealed for experimenters. Participants 
were invited for a baseline and an experimental session, which 
were timed 1 week apart. An overview of the study design and 
measurement schedule is provided in Figure 1.
Measures and Materials
Verbal Suggestions
Before the study, participants were informed that the study 
aimed to investigate individual differences in the sensitivity to 
itch and the role of psychological factors in explaining these 
differences. They were informed that the itch induction method 
would elicit a response similar to a mosquito bite (e.g., that their 
skin may become red and swollen). During the experimental 
session, participants were told that, prior to itch induction, a 
tonic would be applied that influences sensitivity to itch. In 
reality, this tonic was a pink-colored skin disinfectant (Orphi 
Pharma B.V., Dordrecht, the Netherlands). The itch induction 
during the baseline session was used as a reference point for the 
suggestions. In the positive VS groups (I and II), the following 
suggestion was given: “This tonic has an itch-reducing effect and 
will make the skin less sensitive to itch. From previous research 
we know that the application of this tonic will reduce itch for 
most people, meaning around 95 percent of the studied people. 
As such, we expect that you will experience less itch, compared to 
the previous test.” Participants in the negative VS groups (III and 
IV) were given the same information, but negative words were 
used instead of positive words (e.g., “itch-increasing” rather than 
“itch-reducing”).
When participants were allocated to one of the two open-label 
groups, additional instructions were given. For the positive VS 
FIGURE 1 | Overview of the design of the study and the measurement schedule for the different verbal suggestions (VS) groups.
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group, these were: “I just told you that the tonic reduces itch. In fact, 
the tonic is a placebo. From research we know that the expectation 
that a remedy reduces itch will really cause people to experience less 
itch. This is caused by different processes, for example itch-reducing 
substances that are released in the brain. These substances are also 
released when people know that they receive a placebo. So, even 
though I told you this, you will likely experience less itch during the 
test.” For the open-label negative VS groups, negative words were 
again used in the instructions instead of positive words. During 
application of the tonic, the provided suggestions and, if applicable, 
open-label instructions were briefly repeated in a single sentence.
Expected Itch
Expected itch in response to histamine iontophoresis was 
assessed on a Numeric Rating Scale (NRS) ranging from 0 (“no 
itch”) to 10 (“worst itch imaginable”). Participants rated the 
amount of itch they expected to experience during iontophoresis 
twice: once at the start of the baseline session and once during 
the experimental session, following the verbal suggestions but 
prior to histamine iontophoresis.
Histamine Iontophoresis
Histamine was applied to the skin by transdermal iontophoresis 
(Chattanooga Group, Hixson, TN, USA). This method has 
been previously validated and reliably induces itch in healthy 
populations (22, 28, 29, 35). A 0.6% diphosphate (equivalent to 1% 
histamine dihydrochloride) histamine solution was prepared in 
distilled water with propylene glycol and hypromellose 4,000 mPa 
by the local pharmacy. In preparation of iontophoresis, the skin 
was cleaned with either a transparent disinfectant (alcohol 
70%; baseline session) or a pink-colored disinfectant (0.5% 
chlorhexidine in alcohol 70%, with rhodamine; experimental 
session) suggested to be itch-reducing or itch-increasing, 
depending on placebo or nocebo condition. A 2.5-cc electrode 
(Iogel, Iomed, DJO Global, Hannover, Germany; active surface: 
11.7 cm2) was treated with the histamine solution and applied to 
the volar side of the non-dominant forearm. A reference electrode 
was placed on the volar side of the upper arm. The electrode 
nodes were spaced approximately 10 cm apart. Histamine was 
applied to the skin by iontophoresis with a current level set at 0.4 
mA for 2.5 min, following which the electrodes and any residual 
histamine were removed from the skin.
Self-Reported Itch
Self-reported itch in response to histamine iontophoresis was 
assessed using the same 0–10 NRS as described under Expected 
Itch. During iontophoresis, participants continuously rated itch 
using a vertical bar slide depicting the NRS. Scores were sampled at a 
10-Hz rate using E-Prime 2.0 (42). Directly following iontophoresis, 
mean itch was verbally assessed by asking participants how much 
itch (on a 0–10 scale) they experienced in general during the test. 
From 1 to 4 min after iontophoresis, participants were asked to 
rate self-reported itch every 30 s on the bar slide as a follow-up 
period. The primary study outcome was the area under the curve 
(AUC) of itch during the 2.5 min of iontophoresis. Secondary 
outcomes were maximum itch reported during the 2.5 min of 
iontophoresis, verbally assessed mean itch, and AUC itch during 
the 4-min follow-up. AUC of itch and maximum itch during 
iontophoresis were computed using MATLAB Release 2012b (The 
MathWorks, Inc., Natick, MA, USA).
Subjective Skin Response
Participants filled in the Sensitive Scale-10 (SS-10) (43) to 
measure their subjective skin response. The SS-10 contains 10 
items, of which 9 items assessed specific skin symptoms (e.g., 
itch, pain, general discomfort, and heat sensations). Participants 
were asked to rate in what intensity they had experienced these 
symptoms over the past 3 days as a baseline measurement, as well 
as during histamine iontophoresis. Symptoms were rated on NRS 
ranging from 0 (“zero intensity”) to 10 (“intolerable intensity”). 
An additional symptom (“redness of the skin”) was assessed on 
a 0–10 NRS (43). Total scores were calculated by summing all 
items and ranged from 0 to 100. Cronbach’s alpha ranged from 
.83 to .87 in the current study for baseline and post-iontophoresis 
assessments of the SS-10.
Physical Skin Response
Wheal size and flare areas following histamine application were 
measured after the 4-min follow-up period after the iontophoresis 
test. The size of the skin response was measured by drawing the 
outline of the redness and thickening of the skin onto a 1-cm2 
gridded transparent sheet with a 0.4-mm black permanent 
marker (Staedtler, Germany). The sheets were scanned and then 
retraced using ImageJ software (44), after which the wheal and 
flare area (in cm2) were calculated. In addition, skin temperature 
was measured following iontophoresis, using a handheld infrared 
digital thermometer (accuracy ± 2.0 °C, resolution 0.1 °C; 
BaseTech, Conrad Electronic Benelux B.V.). Measurements were 
taken with the thermometer held vertically and approximately 
1 cm above the center of the histamine application area. To 
control for individual differences in skin temperature, a baseline 
measurement was taken prior to iontophoresis, with change from 
baseline temperature being used as the outcome measure.
Procedures
Prior to participation, written information regarding the study 
was provided, and volunteers were asked to fill in an online 
questionnaire assessing the study’s inclusion and exclusion criteria. 
When volunteers were considered eligible for participation, they 
were invited to the lab for a 30-min baseline session and a 45-min 
experimental session, which were timed 1 week apart. At the 
start of the baseline session, the study procedures were explained, 
and written informed consent was provided. Next, personality 
questionnaires were administered, which are not further described 
here as they are unrelated to the aim of the current study. Baseline 
measurements of itch expectation and subjective skin responses 
in the past 3 days were taken. Next, the skin of the non-dominant 
forearm was disinfected, and electrodes were placed on the arm, 
after which the histamine test was conducted. Measurements 
of itch and physical skin responses were taken, followed by 
an assessment of subjective skin responses. After 1 week, the 
experimental session took place. First, the general procedure of 
the second session was explained, and verbal suggestions were 
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given (the content of which depended on group allocation). 
Measurements of post-VS expected itch and of subjective skin 
responses in the past 3 days were taken. Next, the skin was cleaned 
using the pink disinfectant, during which the verbal suggestions 
were briefly repeated. Histamine iontophoresis was conducted; 
and measurements of itch, physical skin response, and subjective 
skin response were taken. At the end of the session, participants 
were asked to fill in a final questionnaire assessing the general 
amount of itch experienced during both baseline and post-VS 
iontophoresis and, for the open-label groups only, how believable 
and convincing participants thought the open-label rationale was 
(on a 0–10 NRS). Upon completion, they were debriefed on the 
true purpose of the study. For each session, participants received 
a compensation of €7.50.
Statistical Analyses
As input for the power calculation, we used the effect size of Cohen’s 
d = 1.10, that was found by Napadow et al. (25), who investigated 
nocebo effects induced by an inert substance (i.e., a sham allergen 
solution) on itch. As the current study investigated not only 
nocebo effects following application of an inert substance but also 
placebo effects, and both were investigated under closed-label and 
open-label conditions, a more conservative effect size of d = 0.90 
was used for computation of sample sizes for the separate open-
label and closed-label analyses. A power calculation for an analysis 
of covariance (ANCOVA) using G*Power 3.1 (45) indicated that 
21 participants per group would be needed at a power of β = .80 
and a significance level of α = .05 for the primary outcome of AUC 
itch during iontophoresis in the experimental session between the 
(separate closed-label or open-label) positive verbal suggestion 
group and the negative verbal suggestion group while controlling 
for AUC itch at baseline. A missing data rate of 10% was taken into 
account, resulting in a sample size of 23 participants in each group.
Analyses were performed using SPSS 21.0 for Windows 
(IBM SPSS Inc., Chicago, IL, USA). Normal distribution of the 
variables and the assumptions of each analysis were checked 
prior to analysis. To test for group differences in demographics 
and baseline variables, chi-square tests and one-way analyses 
of variance (ANOVAs) were conducted. As a priori determined 
primary analysis, differences between the combined negative VS 
groups and positive VS groups in AUC itch during iontophoresis 
were assessed by a general linear model (GLM) ANCOVA, 
controlled for AUC itch during baseline iontophoresis. Similar 
analyses were conducted for the secondary outcome parameters, 
maximum itch during iontophoresis, mean itch (assessed 
verbally following iontophoresis), AUC itch during the 4-min 
follow-up, subjective skin response, and the physical skin 
response parameters.
Due to technical difficulties with the NRS bar slide and 
E-Prime, data of some participants (n = 6) were missing for the 
analyses of AUC itch and maximum itch during iontophoresis. 
Data of one participant were missing for the skin temperature 
measurements. For those variables that were non-normally 
distributed (i.e., AUC itch during follow-up), a change score was 
calculated by subtracting baseline scores from those measured 
post-VS (with zero indicating no change, negative scores 
indicating a decrease, and positive scores indicating an increase 
from baseline to post-VS). A GLM ANOVA was then performed to 
detect differences in change scores between groups. For expected 
itch following suggestions, an ANOVA was also conducted. For 
each AN(C)OVA, Cohen’s d was calculated, and the following 
interpretations were used: small effect size 0.20, medium effect size 
0.50, and large effect size 0.80 (46). When appropriate, covariate-
adjusted means were used for calculation of Cohen’s d. In addition, 
paired sample t-tests were conducted within each group to assess 
changes in each outcome parameter from the baseline to post-VS 
measurements. In order to examine whether the effects of verbal 
suggestions were similar regardless of participants knowing about 
the expectation induction, all analyses were repeated for the 
separate open-label and closed-label conditions. As the effects 
of suggestions were expected to be similar under open-label and 
closed-label contexts, differences between open- and closed-label 
groups were not tested statistically. Rather, effect sizes generated 
by the separate open-label and closed-label analyses were used 
for indirect comparisons.
To explore potential group differences in the strength of 
associations between the process measure of post-VS itch 
expectation and the outcome measures of itch and skin response, 
Pearson’s r correlations were calculated within each group, and 
Cohen’s q was computed as an effect size for the difference in strength 
of association, with the following categories of interpretation: 
no effect < 0.10, small effect size 0.10 < 0.30, medium effect size 
0.30 < 0.50, and large effect size ≥ 0.50 (46). For AUC itch during 
follow-up, Spearman’s rho was calculated. The open-label groups 
were compared on how believable and convincing participants 
thought the open-label rationale was by independent-samples 
t-tests. All analyses were conducted two sided with α = .05. For the 
secondary analyses (i.e., AN(C)OVAs and paired-sample t-tests 
for separate open-label and closed-label analyses), Bonferroni’s 
correction for multiple comparisons was used, thus resulting in a 
significance level of α/2 = .025. To correct for alpha inflation due 
to multiple itch outcomes, an additional Bonferroni’s correction 
was applied for the secondary itch outcomes, resulting in a 
significance level of α/3 = .017 for the combined-group analyses 
and (α/3)/2 = .008 for the separate-group analyses of the secondary 
itch outcomes. All values described in the Results section represent 
mean ± SD, unless stated otherwise.
RESULTS
Participants
A total of 138 potential participants expressed interest in 
the study, of whom 44 were not included (18 had somatic or 
psychological morbidity, 4 were non-proficient in the Dutch 
language, and 22 gave no response following screening). 
Two participants dropped out after the baseline session and 
were replaced. This resulted in the intended sample size of 
92 participants (16 males, 17.4%; 76 females, 82.6%), whose 
age ranged from 18 to 30 (M = 21.8  ± 2.7). Participants were 
randomized into 1) the open-label positive VS group (n = 22), 
2) the closed-label positive VS group (n = 23), 3) the open-label 
negative VS group (n = 23), or 4) the closed-label negative VS 
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group (n = 24). The groups did not differ in demographic factors 
(all p ≥ .42), baseline itch expectation prior to iontophoresis 
(p  = .13), baseline self-reported itch parameters (all p ≥ .58), and 
baseline subjective and physical skin condition (all p ≥ .12). An 
overview of the means and standard deviations of the baseline 
and outcome measures is presented in Table 1 (combined open-
label and closed-label groups) and in Supplementary Table S1 
(separate open-label and closed-label groups).
Expected Itch
A large-sized effect of verbal suggestions on expected itch was found; 
F(1,90) = 20.94, p < .001, Cohen’s d = 0.96. As illustrated in Figure 2, 
expected itch following suggestions was significantly lower in the 
combined positive VS groups (M = 2.62 ± 1.82) compared with the 
combined negative VS groups (M = 4.41 ± 1.93).
A secondary analysis showed a large-sized effect of suggestions 
in the open-label groups [F(1,43) = 15.84, p < .001, Cohen’s 
d = 1.21] and a medium-sized effect in the closed-label groups 
[F(1,45) = 6.15, p = .017, Cohen’s d = 0.74], both indicating 
significantly lower expected itch in the positive VS group (open label: 
M = 2.35 ± 1.88; closed label: M = 2.88 ± 1.77) than in the negative 
VS group (open label: M = 4.59 ± 1.91; closed label: M = 4.24 ± 1.99).
Primary Itch Measure: Area Under the 
Curve (AUC) of Itch during Histamine 
Iontophoresis
For the primary outcome AUC itch, a small-sized non-significant 
difference between the combined positive VS groups and the 
combined negative VS groups was found; F(1,83) = 1.75, p = .19, 
Cohen’s d = 0.29. Secondary analyses for the separate open- and 
closed-label groups revealed similar findings (both p ≥ .31; see 
Figure 3). Within-group analyses of baseline to post-VS changes 
indicated that AUC itch decreased marginally in the combined 
positive VS groups [t(39) = 1.98, p = .055] but did not change 
in the combined negative VS groups [t(45) = −0.19, p = .85]. 
No within-group changes in AUC itch from baseline to post-VS 
were detected for the separate open- and closed-label groups (all 
p ≥ .12). An overview of within-group comparisons for AUC itch 
and other outcome measures is presented in Table 2 (combined 
TABLE 1 | Means ± standard deviations for the combined open- and closed-label positive and the combined open- and closed-label negative verbal suggestion groups.
Combined open- and -closed-label
n Positive VS (n = 45) Negative VS (n = 47) AN(C)OVA
p-value Cohen’s d
Process measure 
Pre-iontophoresis itch expectation 92 5.15 ± 1.95 4.82 ± 1.75 .40
Post-VS itch expectationA 92 2.62 ± 1.82 4.41 ± 1.93  <.001 0.96
Baseline histamine iontophoresis
AUC itchB 88 369.79 ± 241.69 361.35 ± 230.24 .87
Maximum itch 88 3.95 ± 2.44 3.78 ± 2.26 .73
Mean itchC 92 3.10 ± 1.90 2.93 ± 1.75 .66
Post-VS histamine iontophoresis
AUC itchB,D 86 314.61 ± 237.34 367.54 ± 266.63 .19 0.29
Maximum itchD 86 3.44 ± 2.54 3.81 ± 2.45 .24 0.26
Mean itchC,D 92 2.83 ± 1.93 3.19 ± 2.09 .076 0.38
Change from baseline to post-VS scores
AUC itch during follow-upB,E 90 −3.38 ± 6.37 0.02 ± 6.88 .017 0.52
Baseline skin response to iontophoresis
Subjective skin responseF 92 24.37 ± 11.77 22.78 ± 12.25 .53
Wheal area (cm2) 92 10.52 ± 3.47 11.09 ± 3.00 .40
Flare area (cm2) 92 47.74 ± 11.05 48.16 ± 12.45 .86
Change in skin temperature (°C)G 91 1.70 ± 1.01 1.58 ± 1.22 .61
Post-VS skin response to iontophoresis
Subjective skin responseD,F 91 21.08 ± 12.31 20.79 ± 12.21 .58 0.12
Wheal area (cm2)D 92 10.12 ± 3.80 10.68 ± 3.69 .78 0.06
Flare area (cm2)D 92 45.54 ± 13.11 47.17 ± 11.75 .54 0.13
Change in skin temperature (°C)D,G 90 1.83 ± 1.15 2.34 ± 1.62 .018 0.52
AVS, verbal suggestions. BAUC, area under the curve. CAssessed verbally on a Numeric Rating Scale ranging from 0 to 10. DGroup differences assessed by ANCOVA, controlled  
for baseline. Cohen’s d was calculated with the estimated marginal means (controlled for baseline). ECalculated as post-VS measure–baseline measure (session 2–session 1)  
and corrected for significant outliers. FAs measured by an adjusted version of the Sensitive Scale-10 (43). GCalculated as post-iontophoresis temperature–pre-iontophoresis 
temperature.
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open-label and closed-label groups) and Supplementary Table 
S2 (separate open-label and closed-label groups).
Secondary Itch Measures during and 
Following Histamine Iontophoresis
Maximum Itch and Mean Itch during Iontophoresis
Findings for maximum itch during iontophoresis were similar to 
those of AUC itch, with no effects of suggestions for the combined 
as well as separate groups (all p ≥ .24) and a marginal decrease 
from baseline to post-VS exclusively for the combined positive 
VS groups [t(39) = 2.00, p = .053]. The combined positive VS 
groups showed a small-sized tendency to report lower (post-
iontophoresis-assessed) mean itch (M = 2.83 ± 1.93) than did the 
combined negative VS groups (M = 3.19 ± 2.09); F(1,89) = 3.22, 
p = .076, Cohen’s d = 0.38. No effects of verbal suggestions were 
found when open- and closed-label groups were separated, nor 
were changes from baseline to post-VS scores detected for any of 
the groups (all p ≥ .19).
AUC of Itch during Follow-Up Following Iontophoresis
A significant and medium-sized difference in the change scores 
of AUC for itch during the 4-min follow-up was found when 
open- and closed-label groups were combined [F(1,88) = 6.09, 
p = .016, Cohen’s d = 0.52], with AUC itch during follow-up 
decreasing significantly in the combined positive VS groups 
(M = −3.73 ± 7.55) compared with the combined negative VS 
groups (M = 0.02 ± 6.88). A small-sized non-significant effect of 
verbal suggestions was found in the open-label groups; F(1,43) = 
2.11, p = .15, Cohen’s d = 0.43, and a marginal and medium-
sized effect in the closed-label groups, in the same direction as 
for the combined groups; F(1,43) = 4.94, p = .032, Cohen’s d = 
0.67. A significant change from baseline to post-VS in AUC itch 
during follow-up was demonstrated for the combined positive 
VS groups [t(42) = 3.24, p = .002]. In the combined negative 
VS groups, however, no change was detected [t(46) = −0.02, 
p = .98]. Separating open- and closed-label groups revealed a 
non-significant change within the open-label positive VS group 
[t(21)  = 1.87, p = .075] and a significant change within the 
closed-label positive VS group [t(20) = 3.14, p = .005].
Skin Response
Subjective Skin Response (SS-10)
For subjective skin response following the histamine test, no 
significant difference was found between the combined positive 
and negative VS groups, nor between the separate open- and 
closed-label positive and negative VS groups (all p ≥ .12). A 
significant decrease in subjective skin response from baseline to 
post-VS was demonstrated in the combined positive VS groups 
[t(43) = 2.59, p = .013], but not in the negative VS groups [t(46) = 
1.61, p = .12]. When analyses were conducted for separate open- 
and closed-label groups, a significant decrease was demonstrated 
only for the closed-label positive VS group; t(22) = 3.75, p < .001.
Physical Skin Response
No effects of verbal suggestions on wheal or flare areas were 
found for either the combined or separate open- and closed-label 
groups (all p ≥ .23). Regarding skin temperature, the combined 
positive VS groups showed a medium-sized lower increase 
in skin temperature from before to after iontophoresis (M = 
1.83  ± 1.15) than did the combined negative VS groups (M = 
2.34 ± 1.62); F(1,87) = 5.84, p = .018, Cohen’s d = 0.52. In the 
same direction, marginally significant medium-sized effects of 
verbal suggestions on skin temperature increase were found in 
the open-label [F(1,41) = 3.01, p = .090, Cohen’s d = 0.54] and 
closed-label groups [F(1,43) = 2.93, p = .094, Cohen’s d = 0.52], 
respectively. Within-group comparisons for both combined and 
separate open- and closed-label positive and negative VS groups 
showed that skin temperature increased significantly from 
baseline to post-VS for the negative VS groups (all p ≤ .048), but 
not for the positive VS groups (all p ≥ .12).
Associations between Expected Itch  
and the Outcome Measures of Itch
In the combined open- and closed-label groups, expected itch 
following suggestions was significantly and positively associated 
FIGURE 2 | Mean Numeric Rating Scale (NRS) score for post-verbal suggestions (VS) itch expectation with the standard error of the mean (SEM) for (A) the 
combined open- and closed-label positive VS group (n = 45) and negative VS group (n = 47); (B) the open-label positive VS group (n = 22) and open-label negative 
VS group (n = 23); and (C) the closed-label positive VS group (n = 23) and closed-label negative VS group (n = 24). ***p < .001, *p < .05.
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FIGURE 3 | Mean area under the curve (AUC) of self-rated itch during histamine iontophoresis in the baseline and experimental session, with the standard error of 
the mean (SEM) for (A) the combined open- and closed-label positive VS group (n = 40) and negative VS group (n = 46); (B) the open-label positive VS group (n = 21) 
and open-label negative VS group (n = 22); and (C) the closed-label positive VS group (n = 19) and closed-label negative VS group (n = 24). n.s. = not significant 
(p > .05).
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with all itch measures during and following iontophoresis (all r ≥ 
.43, all p ≤ .01). Comparisons of the strength of the association 
between expected itch and the itch outcome measures showed 
small-sized to no differences in associative strength between 
the combined positive and combined negative VS groups (all 
Cohen’s q ≤ 0.15). In the separate open-label and closed-label 
groups, findings were similar, with one exception: in the open-
label positive VS group exclusively, itch expectations were not 
associated with mean itch and AUC of itch during follow-up 
(both p ≥ .11). An overview of Pearson’s r and Spearman’s ρ 
correlation coefficients can be found in Table 3 (combined open- 
and closed-label groups) and Supplementary Table S3 (separate 
open- and closed-label groups).
Open-Label Instruction Believability
Overall, participants in the open-label conditions rated the 
instructions as very clear (M = 7.90 ± 2.32). Ratings on how 
convincing the instructions had been were more ambiguous 
(M  = 5.37 ± 2.46). In general, participants in the open-label 
groups believed that expectations are able to influence itch 
(M = 6.49 ± 1.97) but rated the extent in which their own itch 
experience was influenced by the application of the tonic as low 
(M = 3.81 ± 2.43). Groups did not differ in their ratings of the 
instructions (all p ≥ .21).
DISCUSSION
The current study investigated whether positive and negative 
outcome expectations, induced by open-label and closed-label 
positive and negative verbal suggestions regarding an inert tonic, 
could influence self-reported itch in response to a histamine test. 
For the first time, open- and closed-label placebo effects for itch 
were investigated within a single study, including a comparison 
with open- and closed-label nocebo effects. It was demonstrated 
that both open-label and closed-label verbal suggestions were able 
to influence itch expectations. For the primary outcome of area 
under the curve for itch during histamine iontophoresis, a small-
sized but non-significant effect of verbal suggestions was found. 
Participants in the combined open- and closed-label positive VS 
groups reported lower itch during an immediate follow-up period 
TABLE 2 | Within-group mean changes from baseline and separate paired sample t-test results for the combined open- and closed-label positive verbal suggestion 
groups and combined negative verbal suggestion groups.
Combined open- and closed-label positive VS groups  
(n = 45)
Combined open- and closed-label negative VS groups 
(n = 47)
n Mean change t p n Mean change t p
Histamine iontophoresis
AUC itchA 40 −46.91 1.98 .055 46 6.19 −0.19 .85
Maximum itch 40 −0.44 2.00 .053 46 0.02 −0.07 .94
Mean itchB 45 −0.26 1.34 .19 47 0.26 −1.30 .20
Post-iontophoresis follow-up
AUC itchA 43 −3.73 3.24 .002 47 0.02 −0.02 .98
Skin response to iontophoresis
Subjective skin responseC 44 −3.30 2.59 .013 47 −2.00 1.61 .12
Wheal area (cm2) 45 −0.40 0.79 .43 47 −0.41 0.87 .39
Flare area (cm2) 45 −2.20 1.31 .20 47 −0.99 0.50 .62
Change in skin temperature (°C)D 44 0.14 −0.88 .38 46 0.76 −3.88  <.001
Mean change was calculated as post-verbal suggestions score–baseline score, with negative values indicating a decrease from baseline and positive scores indicating an increase 
from baseline. AAUC, area under the curve. BAssessed verbally on a Numeric Rating Scale ranging from 0 to 10. CAs measured by an adjusted version of the Sensitive Scale-10 (43). 
DCalculated as post-iontophoresis temperature–pre-iontophoresis temperature.
TABLE 3 | Within-group Pearson’s r and Spearman’s rho correlations for the 
process measure of post-VS itch expectation and outcome measures of 
self-reported itch and skin response for the combined open- and closed-label 
group comparisons, with Cohen’s q as estimate of the difference in effect size 
between groups.
Combined open- and closed-label groups
Positive VS 
(n = 45)
Negative VS 
(n = 47)
Cohen’s 
q
Post-VS histamine 
iontophoresis
AUC itchA .67*** .58*** 0.15
Maximum itch .63*** .59*** 0.06
Mean itchB .52*** .60*** 0.12
Post-VS follow-up on 
iontophoresis
AUC itch during 
follow-upA,C
.43** .49*** 0.08
Post-VS skin response 
to iontophoresis
Subjective skin 
responseD
.50*** .59*** 0.13
Wheal area (cm2) −.09 −.01 0.08
Flare area (cm2) .03 −.23 0.26
Change in skin 
temperature (°C)E
.04 −.19 0.23
AAUC, area under the curve. BAssessed verbally on a Numeric Rating Scale ranging 
from 0 to 10. CCalculated using the non-parametric Spearman’s rho. DAs measured by 
an adjusted version of the Sensitive Scale-10 (43). ECalculated as post-iontophoresis 
temperature–pre-iontophoresis temperature. **p < .01; ***p < .001.
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after iontophoresis compared to the negative VS groups. Post hoc 
tests indicated that this was mostly due to differences between 
positive and negative VS groups under closed-label conditions. 
In addition, a significantly smaller increase in skin temperature 
was observed in the combined positive VS groups compared 
with the negative VS groups, but no effects on other markers of 
the physical skin response to histamine were found. Overall, the 
current study shows that verbal suggestions regarding a topical 
application of a substance can influence expectations for itch, 
regardless of whether or not participants know about receiving 
suggestions, and provides limited evidence that these suggestions 
may influence itch and skin response in response to histamine.
The findings that verbal suggestions were able to influence 
itch in the follow-up period after histamine iontophoresis are 
in line with a previous study that found medium-to-large-
sized effects of positive suggestions on histamine-induced itch 
(24). While that particular study made use of a cream to help 
induce placebo effects, the current study used a pink-colored 
tonic. Potentially, the use of this particular attribute may have 
led towards smaller effects in the current study, since a cream 
could be perceived as a common treatment for itch by some 
participants, could trigger previously learned associations, 
and could thus potentially elicit stronger effects overall (47). 
Moreover, negative verbal suggestions did not elicit negative 
expectations for itch in the current study and did not increase 
itch either during or following the histamine test, which is not 
in line with previous evidence for verbal suggestion-induced 
nocebo effects in itch (25, 26, 28). It should be noted though 
that these previous studies have induced nocebo effects 
through negative suggestions regarding the experimental 
itch induction method that was used, whereas the current 
study provided suggestions regarding the topical application 
of an attribute prior to itch induction. While this did allow 
for a direct comparison of positive and negative expectation 
induction, potentially, it may have influenced the credibility 
of the negative verbal suggestions as well. Topical application 
of, for example, a cream or tonic in a laboratory setting might 
be associated more easily with symptom reduction rather 
than worsening of symptoms. In comparison, information 
regarding an experimental itch induction method, though 
less clinically relevant, may provide a more neutral basis for 
induction of nocebo effects through suggestions. Alternatively, 
although the baseline histamine application was valuable for 
participants as a comparison point for the second application, 
nocebo effects induced through negative verbal suggestions 
could have been influenced by participants being less anxious 
about the second histamine test, in comparison with the 
first test (since participants were generally unfamiliar with 
histamine iontophoresis prior to participating in the study). 
Future research may utilize a counterbalanced design to 
examine this more in detail. Likewise, more research is needed 
to investigate under which circumstances and through which 
attributes placebo and nocebo effects may be elicited for itch.
An effect of negative verbal suggestions on change in skin 
temperature due to histamine application was demonstrated. 
This finding is similar to previous work on placebo effects in 
autonomically controlled parameters and wheal responses 
(26, 48), a meta-analysis of clinical trials demonstrating 
placebo effects on physical outcome parameters controlled 
by the autonomic nervous system (49), and early studies on 
suggestions and hypnosis (50–52). Considering that either the 
outcome measure differed from these previous studies (i.e., skin 
temperature change rather than wheal size) or the expectation 
induction method was different (i.e., verbal suggestions given 
without hypnosis), caution is needed in interpreting these results. 
Moreover, the verbal suggestions in the current study did not 
influence wheal and flare areas to histamine, which is in line with 
most recent studies (24, 29, 35, 53, 54).
Our design allowed for the first time comparisons of effect 
sizes of positive and negative verbal suggestions under open- 
and closed-label conditions for itch. The findings demonstrate 
that positive verbal suggestions are able to significantly reduce 
expectations of itch under both open-label and closed-label 
conditions, with open-label verbal suggestions seemingly 
inducing larger expectancy effects. Overall, the effects of positive 
and negative verbal suggestions on itch were approximately 
similar sized under open-label and closed-label conditions. 
However, some differences between the conditions could be 
seen when examining the within-group changes from baseline. 
Closed-label suggestions appeared slightly more effective for 
itch, as illustrated by the significant within-group changes in 
itch during follow-up from baseline to post-suggestions under 
closed-label conditions. That open-label placebo treatment can 
significantly influence expectations and, potentially, symptoms of 
itch is in line with previous findings on other outcome parameters 
(31, 32, 34–39). It also provides further preliminary support for 
the notion that concealment of treatment is not necessary to elicit 
placebo responses, and that placebo mechanisms can potentially 
be utilized in clinical practice. Small differences between the 
open-label instructions of the current study and previous work 
need to be noted. Previous studies [e.g., Refs. 31–34, 40] began 
their open-label placebo instructions by indicating that the pill 
that was used was a placebo, prior to indicating the efficacy and 
mechanisms of these effects. The current study on the other 
hand began by introducing the tonic as an effective tool for 
itch reduction and explaining that it was a placebo afterwards, 
together with a rationale on why it would still be effective. 
Differences in the order in which this type of information is 
presented may impact the strength of open-label placebo and 
nocebo effects. In addition, previous work has incorporated 
the concept of learning in the open-label instructions (i.e., by 
giving the example of Pavlov’s dog). This aspect has been omitted 
here, as the current study investigates placebo responses evoked 
by conscious expectancy (i.e., verbal information) rather than 
associative learning mechanisms. Potentially, this may have 
influenced the efficacy of the open-label rationale. Some caution 
needs to be taken in interpreting the effects of negative verbal 
suggestions under the separate open-label and closed-label 
conditions, since neither type of negative verbal suggestions was 
able to increase expectations of itch.
Some strengths and limitations need to be taken into 
account. This is the first study that compares open- and closed-
label positive and negative verbal suggestions to elicit placebo 
and nocebo effects in itch and other responses to histamine. 
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Since the study was conducted single blinded, a reporting bias 
cannot be ruled out, as participants may have adjusted their 
answers to the experimenters’ expectations. To minimize 
influences of response bias on assessments of expectations and 
itch, participants used a (computerized) bar slide to indicate 
these parameters. Future research might, however, consider 
using a double-blinded approach. The effect sizes found in the 
current study are considerably small, which may be due to the 
itch stimulus being perceived as low by participants. As such, 
the study may have been underpowered to find small effects, 
which seems to be supported by finding more significant 
effects of the combined open- and closed-label groups than 
for the separate groups. Moreover, the design of the current 
study did not include a no-treatment group. This prevents 
an estimation of a true placebo or nocebo response, as itch 
may reduce from the first to second histamine test regardless 
of group allocation. Though habituation to the itch stimulus 
cannot be ruled out, its role is likely small, since the itch stimuli 
were relatively short and presented with 1 week in between. 
Alternatively, anxiety may have resulted in higher itch ratings 
during baseline. Including a no-treatment group to control 
for these reductions or utilizing a counterbalanced design 
could provide better estimates of a true placebo and nocebo 
response. Lastly, verbal suggestions were given regarding an 
inert tonic. While this approach may have worked for placebo 
induction, potentially, it may have been harder to elicit nocebo 
effects in this manner, as negative consequences regarding 
such a treatment method may be counterintuitive. To compare 
open-label and closed-label nocebo effects for itch, a different 
approach could be needed. For example, future research could 
investigate whether nocebo effects can be induced when the 
effects of an inert substance on itch are introduced as side 
effects of this substance, as changing to such an introduction 
of negative effects may be more closely related to how negative 
effects would be experienced in clinical practice.
In conclusion, this study provides evidence for the first time 
that positive verbal suggestions can induce expectations for itch 
reduction under both open-label and closed-label conditions. 
Suggestions are able to reduce the amount of itch experienced 
after histamine iontophoresis under both open-label and 
closed-label conditions, with closed-label suggestions 
appearing more effective in reducing itch during follow-up. 
However, experienced itch during histamine iontophoresis 
was not influenced by suggestions. Future research may aim to 
investigate under which circumstances and with which type of 
attribute these suggestions could elicit effects for itch. Further 
demonstrating the efficacy of open-label placebo effects may 
help facilitate the application of these effects in clinical practice.
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